Dignity Health

NEW YORK--(BUSINESS WIRE)--ACCESS GPO today announced a preferred, multi-year agreement with Medtronic to support availability of the Affera™ Mapping and Ablation System with Sphere-9™ Catheter in ambulatory surgery centers (ASCs) across the United States. The agreement is designed to help physician-led ASCs gain earlier access to next-generation technology for treatment of cardiac arrhythmias in the ASC setting. This agreement is about broadening the reach of a new, safer treatment and ensuring that independent, physician-led ASCs have a real opportunity to participate in the future of ablation. said Dr. Vivek Reddy. Pulsed field ablation (PFA) is emerging as one of the most important advances in the treatment of atrial fibrillation. In the ASC setting, successful adoption depends not only on the promise of the technology itself, but on whether it can be implemented with the right workflow alignment, efficiency and strategic support. ACCESS GPO is partnering with Medtronic to help ASCs meet that challenge. As a physician-led group purchasing organization focused on electrophysiology in ASCs, ACCESS GPO chose the Affera system and Sphere-9 catheter for its safety, efficacy and versatility for patients. Sphere-9 is an all-in-one, high density mapping and dual energy (radiofrequency and pulsed field) ablation catheter that is being rapidly adopted by electrophysiologists in the U.S. and around the world. In addition to its highly favorable safety and efficacy profile, Sphere-9 provides improved lab efficiency and workflow for physicians to address a variety of different arrhythmias, making it an excellent choice for the ASC environment. “This agreement is about broadening the reach of a new and safer treatment and ensuring independent, physician-led ASCs have a real opportunity to participate in the future of ablation,” said Dr. Vivek Reddy, Director of Cardiac Arrhythmia Services at The Mount Sinai Fuster Heart Hospital and the Mount Sinai Health System in New York City. “As innovation accelerates, physician-led centers should not have to wait for access, nor should the patients they treat.” “Physician governance of partnerships in ASCs is essential to ensure the focus remains on critical success factors such as clinical quality and sustainable adoption while also providing the best treatment for patients,” said Dr. Arash Aryana, Medical Director of Cardiovascular Services and the Cardiac Electrophysiology Laboratory at Mercy General Hospital in Sacramento, California. “Our goal is to support and foster strong physician governance as ASCs expand and evolve.” “With the rise of PFA, this is an exciting time in electrophysiology with safer and more efficient technologies available,” said Dr. Vijay Swarup, Executive Medical Director of Cardiac Electrophysiology at Arizona Heart Rhythm Center in Phoenix, Arizona “With ACCESS GPO, we are enabling physician-led ASCs to gain access to this innovation sooner, with the support needed for successful adoption.” About ACCESS GPO ACCESS GPO is a physician-led group purchasing organization focused on supporting ambulatory surgery centers, with a particular emphasis on cardiac electrophysiology. The organization works to improve access to advanced technologies, strengthen procedural economics, and preserve physician-led governance as more complex cardiovascular care moves into the outpatient setting. By building strategic vendor relationships around those principles, ACCESS GPO aims to strengthen the long-term foundation for advanced cardiac electrophysiology in ASCs. The organization believes that physician-led outpatient centers should be able to deliver high-level electrophysiology care without giving up control over governance, economics, or clinical standards.

This newly FDA-approved system offers a groundbreaking device for adults with RA. VENTURA, Calif., March 11, 2026 /PRNewswire/ -- With nearly 1.5 million Americans suffering from rheumatoid arthritis (RA), a chronic, progressive inflammatory condition, Dignity Health - St. John's Regional Medical Center (SJRMC) proudly announced it has introduced a groundbreaking, FDA-approved treatment known as the Neuroimmune Modulation - the first of its kind across all of California. "This milestone marks a significant advancement in treating rheumatoid arthritis in adults and highlights another example of whole-person care that St. John's provides to the Ventura community," shares Doug Kleam, Hospital President. Dr. Akinwunmi Oni-Orisan and the surgical team successfully performed the first procedure across California this week at SJRMC to treat this debilitating autoimmune disease. "The implementation of neuroimmune modulation is an exciting treatment approach to chronic autoimmune conditions and reflects St. John's commitment to being at the forefront of advanced surgical technologies that better serve our communities," says Dr. Oni-Orisan, neurosurgeon at St. John's. This life-changing device is designed to deliver targeted stimulation to the left vagus nerve to activate the neural pathways that help regulate immune system activity. It is the only FDA-approved neuroimmune modulation device for adults living with moderately-to-severely active RA who are not adequately managed by – or cannot tolerate – existing advanced RA therapies, such as biological and targeted synthetic disease-modifying anti-rheumatic drugs (DMARDs). Clinical outcomes that led to FDA approval of this device were recently published in Nature Medicine. "I'm excited that we can offer our community pioneering technology with unparalleled safety," says Dr. Gita Fatemi, rheumatologist at St. John's. "This approach can lead to significantly improved outcomes for one of the most life-altering autoimmune disorders - rheumatoid arthritis." "We are proud to partner with St. John's to bring neuroimmune modulation therapy to patients in California," said Murthy Simhambhatla, CEO of SetPoint Medical, the developers of the novel neuroimmune modulation device. "As a Southern California–based company, this collaboration represents an important step in expanding access to a new therapeutic approach that targets the neural pathways controlling inflammation. Working with forward-thinking health systems like St. John's helps accelerate our mission to transform the treatment of rheumatoid arthritis and bring meaningful innovation to patients and physicians." If you're living with moderate to severe RA, talk to your rheumatologist or discover the advanced treatment possibilities available at SJRMC: dignityhealth.org/stjohnsregional. About Dignity Health St. John's Regional Medical Center & St. John's Hospital Camarillo Dignity Health-St. John's Regional Medical Center in Oxnard and St. John's Hospital Camarillo in Camarillo comprise the largest non-profit acute care provider in Ventura County. Founded 110 years ago, St. John's Hospitals are nationally recognized for quality care, safety and service. Both hospitals are supported by an active philanthropic Foundation to support new programs and services, as well as to advance the community's access to health care. Learn more at DignityHealth.org/StJohnsRegional or DignityHealth.org/StJohnsHospitalCamarillo. Media Contact: Angela Giacobbe Tel. 818-314-3269 SOURCE Dignity Health 21% more press release views with Request a Demo

NEW YORK , Feb. 11, 2026 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) ("Baird Medical" or the "Company"), a market leader in minimally invasive Microwave Ablation (MWA) technology, today announced the strategic commercial deployment of its technology at Bakersfield Memorial Hospital in California. This launch represents the first ablation case for Benign Thyroid Tumor (or "of its kind") in the vital central California hub of the San Joaquin Valley. This development reinforces Baird Medical's commitment to accelerating patient access to advanced care and solidifies the Company's expanding footprint in key U.S. regional markets. The inaugural procedure was successfully performed by Tim Beck, M.D., a distinguished Endocrine Surgeon at Dignity Health Medical Group. Under Dr. Beck's direction, the clinical team utilized Baird Medical's proprietary platform to deliver precise, minimally invasive outcomes. The procedure demonstrated the system's high-efficiency ablation capabilities and favorable safety profile, validating the technology's value in a high-volume hospital setting. This launch represents a focused execution of Baird Medical's commercial roadmap. By equipping institutions like Bakersfield Memorial with next-generation tools, the Company continues to drive the adoption of interventional therapies, enhancing the standard of care for patients while delivering on its growth objectives. About Baird Medical Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Mayo Clinic, Tulane Medical Center, Columbia University Medical Center, UCSF Medical Center, Weill Cornell Medical Center, and The George Washington University Hospital. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide. Forward-Looking Statements This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements. Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (6) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. The foregoing list of factors is not exclusive. Additional information concerning certain of these, and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Contact: Eric Huang, PR Liaison Baird Medical Investment Holdings Ltd. Phone: +1 (888) 508-6228 Email: ir@bairdmed.com View original content to download multimedia: SOURCE BDMD